top of page

Home
About Us
Education
Support for Patients & Caregivers
Resource Guide
Clinical Trials Guide
Take Action
More

Use tab to navigate through the menu items.

G3 Neuroendocrine Neoplasms (NEN) or High Grade

G3 Neuroendocrine Neoplasms (NEN) or High Grade

Grade 3 NET

Alpha PRRT with Pb-212 VMT
CHM-2101 CAR-T cell for GI Cancers
COMPOSE: PRRT with Lu-177 EDOTREOTIDE versus “Standard of Care” in Well-Differentiated Aggressive G2 & G3 GEP-NETS
ComPareNET: Lu-177 DOTATATE vs CAPTEM in Advanced pNETs
DAREON™-7: DLL-3 For Advanced Neuroendocrine Cancers
IL13Rα2 CAR T Cell Study for Solid Tumor Cancers
Lu-177 + Carboplatin, Etoposide, and Atezolizumab in SCLC
Lu-177 DOTATATE + Olaparib in GEP-NETs
SORENTO™: Subcutaneous Octreotide for GEP-NETs (Cam2029)
(STELLAR-311) Zanzalintinib Versus Everolimus in pNET and epNET with Locally Advanced or Metastatic Neuroendocrine Tumors
SVV-001 + Ipi-Nivo in Patients With Poorly Differentiated (NEC) or Well-Differentiated High-Grade (NET)
SWOG S2104: Adjuvant CAPTEM for High Risk pNET

Neuroendocrine Carcinoma (NEC)

225Ac-ABD147 to Establish Optimal Dose in Patients With SCLC and LCNEC of the Lung That Previously Received Platinum-based Chemotherapy
Alpha PRRT with Ac-225 + Standard of Care in SSTR+ SCLC
Alpha PRRT with Pb-212 VMT
Antibody Drug Conjugate ADCT-701 in Neuroendocrine Tumors and Carcinomas
DAREON™- 5: DLL-3 BiTE for Neuroendocrine Cancers
DAREON™-9: DLL-3 BiTE + Topotecan in Small Cell Lung Cancer (SCLC)
IL13Rα2 CAR T Cell Study for Solid Tumor Cancers
Lu-177 + Carboplatin, Etoposide, and Atezolizumab in SCLC
Lu-177 DOTATATE + Sunitinib in PNETs
SVV-001 + Ipi-Nivo in Patients With Poorly Differentiated (NEC) or Well-Differentiated High-Grade (NET)
SWOG S2012: Immunotherapy (Atezolizumab) + Standard Platinum
Systemic VSV-IFNβ-NIS and Pembrolizumab in Refractory NSCLC and NEC
ZL-1310 in Participants With Selected Solid Tumors

NEUROENDOCRINE CANCER FOUNDATION

PO BOX 370466

DENVER, CO 80237

info@ncf.net

TERMS & CONDITIONS

© 2025 by Neuroendocrine Cancer Foundation

bottom of page